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To assess the role of tumor necrosis factor (TNF) in the appearance of soluble TNF receptors
(sTNFRs), 20 consecutive patients with a clinical diagnosis of sepsis were studied as were 7
chimpanzees after administration of endotoxin (4 ng/kg) with or without pentoxifylline. The
patients had markedly elevated serum levels of sTNFR-p55 and sTNFR-p75 compared with
healthy controls (P < .0001 for both receptors). The levels of both soluble receptors correlated
with simultaneously measured immunoreactive TNF concentrations (p55: r = .63, P < .01; p75: r
= .69, P < .001). In the chimpanzees, endotoxin induced subsequent rises in the serum concen-
trations ofTNF and sTNFRs. Although pentoxifylline reduced the TNF response to intravenous
endotoxin to 20% (P < .05), the appearance of sTNFRs was only moderately inhibited (sTNFR-
p55 to 79% on average, P < .05; sTNFR-p75 to 77%, P = .12). These results indicate that TNF
either does not play an important role in the appearance of sTNFRs in systemic infection or that
a small amount of TNF remaining in the circulation after some bacterial challenges is sufficient
to preserve the secretion of its soluble receptors.
Sepsis is a syndrome characterized by hypotension, vascu-
lar leakage, and failure of multiple organs. Tumor necrosis
factor (TNF) is an important factor for initiation ofthe septic
syndrome [1 ]. Massive induction ofTNF synthesis, resulting
in high concentrations of the protein in the circulation, is a
prerequisite for the development of shock and multiple or-
gan failure in experimental sepsis in animals [2]. In patients
with sepsis, the extent of systemic TNF release correlates
strongly with mortality rates [3, 4]. Administration of TNF
to animals or humans reproduces many of the features of
septicemia [5, 6]. Recently, naturally occurring inhibitors of
TNF activity have been found in the urine ofnormal individ-
uals and febrile patients and in the serum of patients with
renal insufficiency [7-11]. These host mediators, originally
termed TNF-binding proteins, have subsequently been iden-
tified as the soluble extracellular domains of the 55- and
75-kDa membrane-bound TNF receptors [12-16]. Soluble
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TNF receptors (sTNFR-p55 and -p75) compete with the
membrane receptors for binding of free TNF and may there-'
fore have physiologic importance for the regulation of TNF
activity. Indeed, in vitro experiments have revealed that
TNF-binding proteins can block various biologic activities of
TNF [8,10,11,17].
Intravenous administration of endotoxin has been widely
used to study the early events of the host response to sepsis.
Injection of endotoxin induces a rise in the serum levels of
TNF, peaking after 90 min [17, 18], which is followed by the
appearance of sTNFRs [17]. Because of the subsequent ap-
pearances of TNF and its inhibitors, it has been suggested
that the cytokine is involved in the regulation of its own
activity in endotoxemia. This hypothesis is supported by the
fact that TNF is capable of inducing the production of a
TNF-binding protein in vitro [12] and, when combined with
subcutaneous injections ofinterferon-')', in cancer patients in
vivo [19]. Moreover, in children with severe meningococce-
mia, the appearance of TNF seems to precede the appear-
ance of the soluble receptors [20]. We assessed the possible
role of TNF as an intermediate factor in the release of
sTNFRs in sepsis.
Materials and Methods
Study populations and design. Blood was obtained from 20
consecutive patients (15 men, 5 women) admitted with a clini-
cal diagnosis of sepsis to the Intensive Care Unit, Academic
Medical Center, Amsterdam. Ages were 29-79 years (mean,
58.3). Criteria for a diagnosis ofsepsis were as follows [21]: fever
or hypothermia (>38.3 or <35.6°C); tachycardia (>90 beats/
min in the absence of {3-blockade) and tachypnea (respiration
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>20/min or need for mechanical ventilation); and either hypo-
tension (systolic blood pressure ::::;90 mm Hg or a sustained drop
in systolic pressure ~40 mm Hg in the presence ofan adequate
fluid challenge and in the absence ofantihypertensive agents) or
two of the following six signs of systemic toxicity or peripheral
hypoperfusion-unexplained metabolic acidosis (pH ~7.3,
base deficit >5 mmol/L, or an elevated plasma lactate level);
arterial hypoxia (Po2 ~ 75 mm Hg or FIo2 < 250); acute renal
failure (urinary output <0.5 mL/kg/h); elevated prothrombin or
partial thromboplastin time or reduction ofthe platelet count to
less than half the baseline value or < I00,000 platelets/mm3;
sudden decrease in mental acuity; and cardiac index of>4 L/m2
with systemic vascular resistance of <800 dyn s/cm5•
In addition to these human experiments, 7 healthy adult
chimpanzees (Pan troglodytes) were studied after either intrave-
nous injection (n = 4) of endotoxin (4 ng/kg; lot EC-5, Esche-
richia coli 0 113; provided by D. Hochstein, Bureau ofBiologics,
US Food and Drug Administration, Bethesda, MD) or injection
of the same endotoxin dose in combination with an intravenous
infusion of pentoxifylline (n = 3; Trental; Hoechst, Amster-
dam). A total of 500 mg of pentoxifylline was given in 3 h,
starting 30 min before the administration of endotoxin. The
chimpanzees were from the primate colonies of the TNO-ITRI
Primate Center, Rijswijk, Netherlands, and the Laboratory for
Experimental Medicine and Surgery in Primates, New York Uni-
versity School of Medicine, New York. All animals had normal
routine laboratory examinations. They were sedated with keta-
mine chloride (Ketalar; Parke-Davis, Amsterdam) and, after in-
tubation, kept under general anesthesia with nitrous oxide and
halothane (Halothan; Hoechst). All animals were studied for 5 h
after the injection of endotoxin. Other than a mild febrile re-
sponse, there were no adverse effects and all animals were re-
turned to their cages in good health after the experiments. The
chimpanzee studies were part of simultaneous investigations on
the effects of pentoxifylline on endotoxin-induced neutrophil
activation (not reported here).
Sampling and assays. Patients with clinical sepsis were stud-
ied at admission. Chimpanzee venous blood samples were ob-
tained just before the endotoxin injection and at 0.5, 1.0, 1.5,
2.0, 3.0, 4.0, and 5.0 h thereafter. Serum was prepared immedi-
ately, and samples were stored at -70°C until analyzed.
sTNFR-p55 and -p75 were measured with enzyme-bound immu-
nologic assays (Hoffmann-La Roche) [20]. Microtiter plates
(Maxisorp; Nunc, Roskilde, Denmark) were coated overnight at
room temperature with TNF-binding noninhibitory monoclo-
nal antibodies against TNFR-p55 (clone htr-20) or TNFR-p75
(clone utr-4) [22, 23]. Subsequently, the coated wells were
washed, and the remaining protein-binding capacity ofthe wells
was saturated with 1%bovine serum albumin in 200 mM TRIS/
HCl, pH 7.5, and 0.02% Kathon. After the storage buffer was
discarded, samples diluted 1:5 in 0.1 M sodium phosphate
buffer, pH 7.25, containing 10% fetal bovine serum, 0.1%
phenol, 0.1 %Tween 20, and 0.02% Kathon were added to the
wells. Standard curves were constructed with recombinant
sTNFR-p55 or -p75. Next, peroxidase-conjugated recombinant
human TNF was added, and the mixtures were incubated for 2
days at 4°C. After wells were washed four times with distilled
water, 0.05% Tween 20 and o-phenyldiamine dihydrochloride
substrate were added and incubated for 15-20 min. The reac-
tion was stopped with H2S04 and read at 490 nm.
The specificity of the assays has been confirmed by experi-
ments in which the binding of the detecting recombinant TNF
to sTNFRs could be prevented either by addition of an excess
(20 ~g/mL) of unlabeled TNF or by replacing the anti-TNFR
monoclonal antibodies by nonspecific antibodies [24]. In addi-
tion, the linearity ofthe assays was verified using natural TNFRs
from celllysates ofHL-60 cells and by recombinant TNFR-p55
and -p75. The concentrations of both sTNFRs were calculated
from the amount of bound labeled TNF using a I: I binding
stoichiometry between TNF and sTNFR. The concentrations
calculated in this way were consistent with those obtained by
using recombinant sTNFRs as the standard [24]. The serum
concentrations of TNF were determined by an assay (IRMA;
Medgenix, Fleurus, Belgium). This assay measures TNF regard-
less of whether it is complexed with its soluble receptors and is
therefore not disturbed by high circulating concentrations of
sTNFRs [25].
Serum TNF activity was determined in a biologic assay using
WEHI-164 mouse fibrosarcoma cells [26]. They were collected
during logarithmic growth and suspended at a concentration of
4 X 105/mL in RPMI 1640 containing 10% fetal calf serum and
actinomycin D (I ~g/mL). Volumes of the suspension (50 ~L)
were added in triplicate to equal parts of the serum sample to be
tested (starting at a 1: 10 dilution) in flat-bottom 96-well plates
(Maxisorp; Nunc) and incubated at 37°C for 18 h. Cytotoxicity
was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyl tetrazolium bromide (MTT) cytotoxicity assay. After ad-
dition of 20 ~L of MTT (5 mg/mL in PBS) to each well and
incubation at 37°C for 4 h, 100 ~L of lysis buffer (20% wt/vol
SDS in 50% dimethyl fluoride) was added; incubation was con-
tinued overnight, and absorbance was read at 578 nm. Concen-
trations of TNF are given in picograms per milliliter; recombi-
nant human TNF (provided by Bayer, Wuppertal, Germany)
was used as the reference standard. The detection limit of the
assay is I pg/mL (i.e., in serum, 10 pg/mL).
Statistical analysis. All values are given as means ± SE. The
differences in results between patients with sepsis and normal
humans were analyzed by Wilcoxon rank sum test. Correlations
were calculated using the Pearson test. In the chimpanzee stud-
ies, differences in results obtained with endotoxin alone and
with endotoxin combined with pentoxifylline were analyzed us-
ing analysis of variance. P < .05 represented a significant differ-
ence.
Results
Patients with clinical sepsis. Admission Apache II scores
of the 20 patients with clinical diagnoses of sepsis ranged
from 18 to 47 (31 ± 1). Overall mortality of these patients
was 50%. Blood cultures were positive in 8 patients (gram-
negative bacteria, 7; yeast, 1). Fifteen patients had positive
cultures from various loci (9, gram-negative bacteria; 4,
gram-negative and -positive bacteria; 2, gram-negative bacte-
ria and yeasts). In 2 patients, all cultures remained sterile.
These patients were not excluded because their clinical
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Figure 1. Serum concentrations ofsTNFR-p55 and sTNFR-p75
in 20 healthy humans and 20 patients with clinical sepsis.
courses were highly suggestive of an ongoing infection. The
duration of illness before blood was obtained was 1-41 h ( 13
± 3).
The serum concentrations of both types of sTNFRs were
markedly elevated in all patients with sepsis compared with
those of healthy controls (figure I). In patients, the serum
levels of sTNFR-p55 were 13.2 ± 1.4 ng/mL versus 1.0 ±
0.3 ng/mL in controls (P < .000 I). Serum sTNFR-p75 con-
centrations were 16.0 ± 1.4 and 1. 5 ± 0.6 ng/mL, respec-
tively (P < .0001). In septic patients, the levels of sTNFR-
p55 correlated significantly with simultaneously measured
levels of immunoreactive TNF (103 ± 26 pg/mL; r = .63, P
< .01; figure 2, top). sTNFR-p75 levels also correlated with
immunoreactive TNF concentrations (r = .69, P < .00 I;
figure 2, middle). The levels of TNF activity (45 ± 31 pg/
mL) showed no significant correlations with sTNFRs con-
centrations (data not shown). Serum levels of sTNFR-p55
correlated with those of sTNFR-p75 (r = .83, P < .00 I; fig-
ure 2, bottom). In this small cohort, the values ofTNF and
its soluble receptors did not differ significantly between sur-
viving and nonsurviving patients (data not shown). In addi-
tion, no significant correlations were found between Apache
II scores and duration of illness and concentrations of TNF
and sTNFRs (data not shown). TNF was not detectable in
the circulation of the healthy controls.
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Figure 2. Correlations between serum concentrations of TNF.
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Discussion
sTNFRs represent soluble forms of the extracellular do-
mains of the cell surface receptors for TNF and probably
arise by proteolytic cleavage. It has been suggested that TNF
itself, in an autocrine manner, is involved in the induction of
sTNFR release. This supposition originates from the obser-
vations that intravenous injection of endotoxin into normal
humans induces subsequent rises in the circulating levels of
TNF and both soluble receptors [17] and that infusion of
recombinant TNF into cancer patients results in a more
rapid rise in TNF-binding protein concentrations than found
in experimental endotoxemia [19].
The present study sought further insight into the role of
TNF in the systemic release of its soluble receptors in sepsis.
In patients with sepsis, the extent of the release of both
sTNFR-p55 and sTNFR-p75 significantly correlated with
immunoreactive (total) TNF levels. In chimpanzees, pentox-
ifylline, a xanthine derivative that has been reported to di-
rectly block endotoxin-induced TNF production at the level
of transcription of the TNF gene [27], reduced the TNF re-
sponse to intravenous endotoxin to 20% of the response ob-
served after administration of endotoxin alone. However,
pentoxifylline only slightly decreased the appearances of
sTNFRs, and was statistically significant only for the p55
form. Therefore, our results suggest either that TNF may not
be an important factor in the secretion of sTNFRs in sys-
temic infection or that TNF is involved in the endotoxin-in-
duced appearance ofits soluble receptors in a nonlinear fash-
ion, that is the small amount of TNF remaining in the
circulation in animals treated with pentoxifylline may have
had a disproportionally large effect on the induction of
sTNFRs.
The septic patients had considerably higher levels of
sTNFRs than did the endotoxemic chimpanzees, despite
lower TNF concentrations. Possibly this apparent discrep-
ancy resulted because the chimpanzees had frequent blood
sampling, which showed the peak TNF levels, but in the
patients the maximal TNF concentration may have been
missed because of the very short serum half-life of the cyto-
kine. In contrast, levels of sTNFRs are more stable and do
not return to baseline as rapidly as does TNF. Thus, the
greater elevation of sTNFRs in the patients with sepsis than
in the endotoxin-treated chimpanzees probably reflects the
more severe bacterial challenge in the first group.
The mechanisms by which the presently observed appear-
ances of sTNFRs occur at cellular levels remain to be estab-
lished. In vitro, shedding of TNF receptors can be induced
by several agents including phorbol esters C5a and A23187
[12, 29]. Moreover, TNF itself can provoke the production
ofa sTNFR by HL-60 cells [12]. A rapid increase in sTNFR-
p55 after a bolus intravenous injection of heparin into nor-
mal humans has been observed, suggesting that sTNFRs are
present in vivo in a storage pool from which they can be
secreted after stimulation [30].
sTNFRs may have a dual function in the body. They re-
tain their affinity for TNF and therefore compete with cell-
associated TNF receptors for binding offree TNF. The even-
tual effect of the formation ofsTNFR-TNF complexes likely
depends on the concentrations ofthe substances and the rate
at which sTNFRs and TNF are cleared from the site ofaction
of the cytokine. In body compartments from which TNF is
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Figure 3. Mean (±SE) serum concentrations ofsTNFR-p55 and
sTNFR-p75 after intravenous administration ofEscherichia coli en-
dotoxin (4 ng/kg; n = 4) or E. coli endotoxin (4 ng/kg) combined
with a 3-h infusion of pentoxifylline (total dose, 500 mg), starting
30 min before endotoxin injection (n = 3), in chimpanzees.
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release of both sTNFRs with kinetics comparable to those in
humans [17]. Pentoxirylline blunted the endotoxin-induced
appearance of sTNFR-p55 (peak concentrations 2.9 ± 0.9
ng/mL after endotoxin alone vs. 2.3 ± 0.1 ng/mL after endo-
toxin with pentoxifylline; P < .05) and reduced the release of
sTNFR-p75 (2.6 ± 1.0 vs. 2.0 ± 0.4 ng/mL, respectively; P
= .12) (figure 3).
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cleared slowly, sTNFRs may serve as carriers for this protein
and even augment its effects by stabilizing its structure and
prolonging its activity [31]. In the circulation, however, from
which TNF is cleared with a very short half-life [6], sTNFRs
probably mainly act as inhibitors of excessive TNF activity,
especially when they are present in relatively high concentra-
tions [17, 31]. Indeed, several in vitro studies have reported
significant inhibition ofTNF activity by sTNFRs when pres-
ent at a 10- to 100-fold molar excess, depending on the
bioassay used [12, 17, 24, 31]. In addition, administration of
recombinant sTNFR-p55 to baboons with lethal bacteremia
attenuates hemodynamic collapse and cytokine release [17].
In our patients with sepsis, sTNFRs circulated in up to 90-
fold molar excess over TNF. Taken together, it is likely that
in sepsis the shedding ofthe extracellular parts ofmembrane-
bound TNF receptors represents a host defense mechanism.
Apparently, this inhibitory system is in many cases insuffi-
cient to prevent the lethal consequences of high blood con-
centrations ofTNF. Increasing the levels ofsTNFRs by exog-
enous administration of recombinant or chimeric forms of
those proteins may therefore prove to be beneficial for the
outcome of sepsis [17, 32, 33].
In conclusion, our study demonstrates that the levels of
sTNFR-p55 and -p75 are elevated in patients with clinical
sepsis. In chimpanzees, strong inhibition of the TNF re-
sponse to endotoxin by treatment with pentoxifylline only
slightly reduced the simultaneously measured circulating
sTNFRs. Our results therefore indicate that if TNF is in-
volved in the induction of the systemic release of its own
soluble receptors in sepsis, the dose-effect relationship is
likely to be nonlinear.
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